Want to join the conversation?
$MRK announced results from two Phase 3 studies evaluating MK-1293, its investigational, follow-on biologic insulin glargine candidate for treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved primary endpoint by demonstrating non-inferiority in change from baseline A1C and similar safety to Lantus.
What are your expectations from $COKE tomorrow?? Will the bear attack the beverage?
People seem to be cold about the $HAL earnings! Honestly, I expected more stock action by now.
$TSLA's Musk says Neuralink will take on AI prominence. Apparently, he wants to avoid a "Terminator" kind situation.
$JCP shares rebounded and now in green territory after saying it will hire 800 consultants as part of a beauty expansion that will include 70 new Sephora store-in-store locations.